Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,101.37
(
-0.11%
)
US TECH 100
25,877.20
(
0.02%
)
Dow Jones
49,443.75
(
-0.01%
)
Brent Oil
93.95
(
3.61%
)
Bitcoin
75,900.43
(
0.01%
)
News Focus
News Focus
Post# of 447418
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

JRoon71

Send PM Follow Ignore
Followers 22
Posts 4660
Boards Moderated 0
Alias Born 01/27/2022

JRoon71

Re: north40000 post# 395461

Monday, 12/12/2022 3:49:50 PM

Monday, December 12, 2022 3:49:50 PM

Post# of 447418
Well, it will obviously depend on the results of the trial.

I wish we had seen some MITIGATE results already.

I think Vascepa is more of a long-Covid play. I say this because I'm not sure of its efficacy for acute treatment. Most trials have shown greatest efficacy in the 2+ year range. Granted, that is for CVD, but I don't know if the pathways are similar.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News